linjc16/ctgov huggingface dataset:
Evaluation of Efficacy and Safety of Ialuset Cream and Gauze in Second-degree Burns on Child

Study Overview
=================
Brief Summary
-----------------
Observational retrospective monocentric study occured in the univeristy hospital center of Bensançon the department of pediatric surgery. Data of patients treated in the hospital between January 2016 and January 2019 have been collected.

Detailed Description
-----------------
Coordinator investigator have put in place a protocol care for children with second degree burns since 2016. It consists in detersion and cleaning of wound, application of ialuset cream and gauzepad (hyaluronic acid) during 21 days. After 21 days if patients are not healed, physician consider to perform grafting

Official Title
-----------------
Observational Retrospective Study Evaluating Efficacy and Safety of Ialuset Cream or Gauzepad in Second Degree Burns Use for Children

Conditions
-----------------
Second-degree Burn of Children

Intervention / Treatment
-----------------
* Device: dressing with hyaluronic acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: second-degree burns less than 20% of the body surface less than 15 years old treated within 24 hours 1st line of treatment with ialuset treated at the center between 2016 and 2019 Exclusion Criteria: patient who refused data collection

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: dressing with hyaluronic acid|Application of ialuset cream or gauzepad (hyaluronic acid)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient rate with complete healing | pourcentage of patient with 100% of reepithelilisation | 21 days |
The Effects of Increased Fructose Ingestion on FGF-21 Levels in Humans

Study Overview
=================
Brief Summary
-----------------
The primary aim of this study is to examine the effect of fructose ingestion on serum FGF-21 levels in humans.

Official Title
-----------------
The Effects of Increased Fructose Ingestion on FGF-21 Levels in Humans

Conditions
-----------------
Fasting

Intervention / Treatment
-----------------
* Dietary Supplement: oral fructose challenge


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ages 18-60 BMI 19-25 kg/m2; 19-23 for Asian subjects Stable weight (variation < 3 kg within 6 months of screening visit) Ability to give informed consent in English Use of medically approved form of contraception Exclusion Criteria: Fasting blood glucose >100 Hemoglobin A1C% > 6.5% Fasting triglycerides >150 Type 1 or type 2 diabetes mellitus diagnosed according to American Diabetes Association criteria Coronary heart disease (history of myocardial infarction, unstable angina pectoris, or congestive heart failure) Uncontrolled hypertension (BP > 160/100 mmHg on or off antihypertensive medication) intravenous drug use Recent weight loss (> 3 kg within 6 months of the screening visit) Gastroparesis Inflammatory or irritable bowel disease Malignancy treated with chemotherapy within the past 3 years Depression or psychosis requiring hospitalization Renal insufficiency (creatinine clearance < 40 ml/min) Transaminases > 2x above the normal range Known liver disease Pregnancy within 6 months of the screening visit Lactation Failure to use medically approved contraceptive methods History of surgery for the treatment of obesity (gastric banding, gastric bypass, gastric stapling) Change in dose of thyroid hormone or antithyroidal medication within 3 months of screening visit History of alcohol abuse within the past 5 years Fructose intolerance Exclusionary medications: Oral steroids Metformin Weight loss medications including nonprescription supplements

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: healthy<br>healthy volunteers will ingest fructose and have FGF21 levels measured | Dietary Supplement: oral fructose challenge<br>* Participants will consume fructose for two weeks and fast for 8 hours before study visits where they will drink a fructose beverage.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in serum FGF21 levels |  | 2 weeks |
Cohort Study of the Clinical Course of Macular Diseases in Kagawa

Study Overview
=================
Brief Summary
-----------------
Macular diseases often cases severe visual impairment. Recent clinical introduction of anti-vascular endothelial growth factor agents may change the clinical course of various macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic macular edema (DME), and so forth. The advance in vitrectomy improve visual outcomes in some maculae diseases, including epiretinal membrane (ERM), macular hole (MH), vitreomacular traction syndrome (VMTS). Patients with such macular diseases are registered and are followed up for 5 years with appropriate treatment for each patient. By the analysis of the correlation between initial examinations and final visual acuity, factors associated with good visual prognosis will be elucidated.

Official Title
-----------------
Cohort Study of the Clinical Course of Macular Diseases in Kagawa (Kagawa Macula Cohort Study)

Conditions
-----------------
Macular Disease

Intervention / Treatment
-----------------
* Drug: ranibizumab, aflibercept, pegaptanib, verteporphin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who visit Department of Ophthalmology, Kagawa University Hospital with macular diseases, such as AMD, PCV, RAP, RVO, DME, ERM, MH, VMTS. Patients who are agreed with the participation of this study. Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Macular disease with adequate treatments<br>Macular diseases can be treated with most appropriate treatment, including pegaptanib, ranibizumab, afibercept, visudyne, or vitrectomy. | Drug: ranibizumab, aflibercept, pegaptanib, verteporphin<br>* ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡<br>* Other names: Lucentis, Eylea, Macugen, Vizudyne;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of best-collected visual acuity from baseline at 5 years |  | Five years after the registration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AMD, PCV, RAP, RVO, DME, ERM, MH, mCNV
The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer

Study Overview
=================
Brief Summary
-----------------
It has been shown that adipokines (resistin, leptin, adiponectin) secreted from adipose tissue and proinflammatory cytokines such as IL-6, TNF-a are associated with the risk of developing colorectal cancer. However, the role of these factors in predicting clinical response to neoadjuvant therapy in rectal cancers is unknown. In this study, the role of serum adipokine levels before neoadjuvant therapy in predicting clinical response in patients with rectal cancer is investigated. For this purpose, blood will be drawn from patients with rectal cancer who will receive neoadjuvant therapy, serum adipokines will be studied and clinical response to neoadjuvant therapy will be compared.

Official Title
-----------------
The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer

Conditions
-----------------
Rectal Cancer Stage III

Intervention / Treatment
-----------------
* Diagnostic Test: serum adipokines


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with locally advanced rectal cancer Exclusion Criteria: below 18 years old patients who did not received neoadjuvant therapyAll

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Low levels of serum adipokines<br> | Diagnostic Test: serum adipokines<br>* Level of serum adipokines will be measured with flow cytometry<br>|
| High levels of serum adipokines<br> | Diagnostic Test: serum adipokines<br>* Level of serum adipokines will be measured with flow cytometry<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients with Rectal Cancer | The Adiponectin, Adipsin, Leptin, Resistin levels will be measured with flow cytometric analysis. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
rectal cancer, neoadjuvant, serum adipokines, leptin, adiponectin
Hyperbilirubinemia After Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
This study aims to evaluate the incidence and risk factors of hyperbilirubinemia following major cardiac or thoracic aorta surgery, and to determine the clinical impacts of the hyperbilirubinemia on postoperative mortality and morbidity.

Detailed Description
-----------------
Patients receiving elective cardiac or thoracic aorta surgery will be monitored for the development of postoperative hyperbilirubinemia. Collection of data will include patient baseline demographic characteristics, laboratory and echocardiographic findings, procedural factors of the surgery, and early postoperative variables. Serial postoperative liver function testings will be done during the hospitalization. Postoperative hyperbilirubinemia is defined as serum bilirubin level of 3mg/dL.

Official Title
-----------------
Hyperbilirubinemia After Major Cardiac or Thoracic Aorta Surgery: Predictors and Clinical Significance

Conditions
-----------------
Cardiovascular Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged over 18 years who are scheduled to undergo elective major cardiac or thoracic aorta surgery. Major cardiac surgery includes coronary artery bypass grafting, pericardiectomy and corrections of cardiac diseases using cardiopulmonary bypassing (valve surgery, tumor excision, arrhythmia surgery, heart transplantation, ventricular reconstruction, pulmonary thromboembolectomy, and atrial or ventricular septal defects closure). Exclusion Criteria: univentricular or one-and-half ventricle repairs presence of known liver cirrhosis or hepatic cancer history of liver transplantation Genetic diseases that affects bilirubin metabolism (i.e. Gilbert syndrome) preoperative bilirubin level of 3mg/dL or more.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All cause-death |  | Within 30 days after surgery or during postoperative hospitalization | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| gastrointestinal or hepatobiliary complications requiring intervention |  | Within 30 days after surgery or during postoperative hospitalization | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hyperbilirubinemia, cardiac, surgery, aorta, prognosis
Study of Psycho-Social Impact of Keloid

Study Overview
=================
Brief Summary
-----------------
Despite their benign nature, keloids may constitute a severe aesthetic, and in some cases, functional problem which translates to various repercussions on person's quality of life, including much stress and insecurities. Keloids are mostly observed between the ages of 10 and 30. Although keloid is a common condition and the investigators can make assumptions about those living with keloids, the investigators do not know the actual impact of the illness on the overall performance of patients' and how this disease, day to day, is impacting their lives. The investigators are conducting this study, aimed to investigate the psychosocial impact of keloid on daily life. Information is collected anonymously. You must be 18 years of age or older to take this survey. Parents can respond on behalf of their children who are not 18 years of age yet. The online survey will take 20-30 minutes to complete.

Official Title
-----------------
Study of Psycho-Social Impact of Keloid

Conditions
-----------------
Keloid

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical Diagnosis of Keloid Informed consent Age above 18 to answer the survey questions Parents shall respond on behalf of their minor children
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Keloid
Feasibility Study for a Web Based Health Coaching Program

Study Overview
=================
Brief Summary
-----------------
This study is designed to compare an intensive lifestyle and activity coaching program (&quot;Sessions&quot;) to usual care for diabetic patients who are sedentary. The question to be answered is whether the Sessions program improves clinical or patient centric outcomes. Recruitment is through invitiation only.

Official Title
-----------------
Mayo-Sessions Clinical Trial

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Behavioral: Web Based Health Coaching


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diabetic patients age 18 or greater Exclusion Criteria: Patients aged 17 or less, Patients with cognition impaired such that they could not comprehend enrollment materials.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Coaching<br>Interventional web based coaching study | Behavioral: Web Based Health Coaching<br> <br> |
| No Intervention: Usual Care<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biometrics | BMI, Blood Pressure | 6 months |
Detection of Enterovirus Genotypes by CRISPR Technology

Study Overview
=================
Brief Summary
-----------------
CRISPR-enterovirus detection system was constructed in this study for detection variety genotypes of enterovirus rapidly in children suspected or diagnosed as enterovirus infection.

Detailed Description
-----------------
To construct CRISPR-enterovirus detection system, we screened the targets, primers and CrRNA and evaluated the capability of this detecting system. Samples of feces, blood and cerebrospinal fluid (the remainder of routine testing samples) from 500 children with suspected or confirmed enterovirus infection were examined using the CRISPR technique. To evaluate the CRISPR-enterovirus detection system, real-time PCR and traditional PCR as comparison method was implemented. The method of real-time PCR and traditional PCR were used to detect enterovirus and analyze the genotypes of enterovirus, respectively. According to the results of CRISPR-enterovirus detection system and the comparison method, the positive coincidence rate, negative coincidence rate and consistency of the two methods were calculated. Furthermore, the sensitivity and specificity of the CRISPR-enterovirus detection system for detection of enterovirus were calculated.

Official Title
-----------------
Rapid Identification and Clinical Transformation of Various Enterovirus Genotypes Based on CRISPR Technology

Conditions
-----------------
Enterovirus Infections

Intervention / Treatment
-----------------
* Other: Non-invasive detection method: CRISPR techonology


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with clinically suspected or confirmed enterovirus infection Exclusion Criteria: Patients with clinical diagnosis of non-enterovirus infection

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Non-invasive detection method: CRISPR techonology|This study was a laboratory diagnostic study without any intervention.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Successful construction of CRISPR-enterovirus detection system | It is a binary variable (yes/no).If the system meet all the following criteria, it would be setted into yes .According to the results of CRISPR-enterovirus detection system and the comparison method： the positive coincidence rate and negative coincidence rate are both over 95.0%; the value of Kappa using to express the consistency of those two methods is over 0.75; the sensitivity and specificity of the CRISPR-enterovirus detection system for detection of enterovirus are over 90.0% and 95.0%; the coefficient of variation between batches is less 15.0%, and each batch detection takes less than 1 hour. | At enrollment |
The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the effect of the anticoagulant(blood thinner) Clexane on the development of leg clots following electrophysiology studies (EPS) and or radiofrequency ablation (RFA). People who suffer heart palpitations will sometimes need hospital admission to undergo an electrophysiology study ( and or a Radiofrequency Ablation)in order to diagnose and or treat their condition. Radiofrequency ablation is a procedure to stop abnormal heart rhythms. EPS/RFA studies require the puncture of the leg veins . Previous experience has shown that following the puncture of leg veins there is a small risk of developing a blood clot in the leg. It is not known whether giving blood thinners (anticoagulants) after the procedure will decrease this risk Enoxaparin Sodium (Clexane) is an anticoagulant used extensively and safely following bone (Orthopaedic) surgery to prevent blood clots from developing in the legs

Official Title
-----------------
The Effect of Enoxaparin Sodium (Clexane) on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.

Conditions
-----------------
Deep Vein Thrombosis

Intervention / Treatment
-----------------
* Drug: Clexane


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing EPS/RFA for the diagnosis and or treatment of SVT based on patient history or ECG evidence. Exclusion Criteria: Patients with a past history of DVT or PE. Patients with a history of clotting disorders Patients with active malignancies Patients requiring full heparinisation during and after the procedure. Chronic atrial flutter and atrial fibrillation ablation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: clexane<br>patients received clexane | Drug: Clexane<br> <br> |
| No Intervention: non clexane<br>no clexane given | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of deep vein thrombosis |  | 1 year |